title: Tandem plasmapheresis and hemodialysis: efficacy and safety.
abstract: BACKGROUND
  Hemodialysis (HD) and plasmapheresis (PE) are usually performed independently on patients who require renal replacement therapy. We analyzed our experience using a technique that performs both modalities simultaneously.
  
  
  METHODS
  Thirty-six patients who were treated with 287 tandem PE and HD (TPH) sessions (mean 7.97 ± 5.6 per patient) were included. PE was connected 30 min after HD started. The mean HD blood flow was 313.7 ± 44 mL/min, the mean PE blood flow was 141 ± 25 mL/min, and the duration of TPH was no longer than 240 min. The heparin dose was similar to that used for a standard HD procedure.
  
  
  RESULTS
  In 287 TPH sessions performed, 10.45% experienced minor complications. There were significant changes in mean blood pressure after connection of the PE system. However, these differences were not clinically relevant since patients remained asymptomatic and they did not require saline infusion. At the end of treatment, 38.9% of patients were no longer dependent on dialysis.
  
  
  CONCLUSIONS
  Our results suggest that TPH is a safe and effective treatment that decreases exposure to an extracorporeal circuit, reducing the risks that are associated with anticoagulation agents and improving the comfortability of the patient.
authors.affiliation: Department of Nephrology, Hospital Universitario Reina Sofía, Córdoba, Spain. mjoseperezsaez@gmail.com
authors.forename: María José
authors.initials: MJ
authors.lastname: Pérez-Sáez
authors.forename: Katia
authors.initials: K
authors.lastname: Toledo
authors.forename: Raquel
authors.initials: R
authors.lastname: Ojeda
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Crespo
authors.forename: Sagrario
authors.initials: S
authors.lastname: Soriano
authors.forename: María Antonia
authors.initials: MA
authors.lastname: Alvarez de Lara
authors.forename: Alejandro
authors.initials: A
authors.lastname: Martín-Malo
authors.forename: Pedro
authors.initials: P
authors.lastname: Aljama
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis / Q000009:adverse effects / Q000379:methods*; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*